Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Depreciation and Depletion (2019 - 2025)

Historic Depreciation and Depletion for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $8000.0.

  • Eton Pharmaceuticals' Depreciation and Depletion fell 3333.33% to $8000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $62000.0, marking a year-over-year increase of 2400.0%. This contributed to the annual value of $50000.0 for FY2024, which is 1363.64% up from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Depreciation and Depletion stood at $8000.0, which was down 3333.33% from $4000.0 recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Depreciation and Depletion ranged from a high of $84000.0 in Q1 2021 and a low of $4000.0 during Q2 2025
  • Over the past 5 years, Eton Pharmaceuticals' median Depreciation and Depletion value was $13000.0 (recorded in 2022), while the average stood at $19210.5.
  • In the last 5 years, Eton Pharmaceuticals' Depreciation and Depletion tumbled by 7500.0% in 2022 and then soared by 21666.67% in 2024.
  • Over the past 5 years, Eton Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $23000.0 in 2021, then plummeted by 43.48% to $13000.0 in 2022, then dropped by 7.69% to $12000.0 in 2023, then surged by 216.67% to $38000.0 in 2024, then plummeted by 78.95% to $8000.0 in 2025.
  • Its Depreciation and Depletion was $8000.0 in Q3 2025, compared to $4000.0 in Q2 2025 and $12000.0 in Q1 2025.